# Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)

> **NCT05116579** · — · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05116579
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-31
- **Primary completion:** 2023-03-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05116579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05116579, "Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05116579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*